FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/02/080193 [Registered on: 10/02/2025] Trial Registered Prospectively
Last Modified On: 09/02/2025
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Single Arm Study 
Public Title of Study   Clinical and Endoscopic Evaluation of Patients Presenting with Acute Upper Gastrointestinal Bleeding 
Scientific Title of Study   Study of clinical and endoscopic profile of patients with acute upper GI bleed 
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Sourab Arora 
Designation  Junior Resident,General medicine  
Affiliation  DY PATIL hospital,Navi Mumbai 
Address  Department of General Medicine Dr D Y Patil Medical College ,Navi Mumbai Thane MAHARASHTRA 400706 India

Thane
MAHARASHTRA
400706
India 
Phone  9888302803  
Fax    
Email  Sourab98a@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Varun Shetty 
Designation  Professor 
Affiliation  DY PATIL hospital,Navi Mumbai 
Address  Department of General Medicine Dr D Y Patil Medical College ,Navi Mumbai Thane MAHARASHTRA 400706 India

Thane
MAHARASHTRA
400706
India 
Phone  9833991811  
Fax    
Email  Shettyvarun81@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Sourab Arora 
Designation  Resident,General medicine  
Affiliation  DY PATIL hospital,Navi Mumbai 
Address  Department of General Medicine Dr D Y Patil Medical College ,Navi Mumbai Thane MAHARASHTRA 400706 Indi

Thane
MAHARASHTRA
400706
India 
Phone  9888302803  
Fax    
Email  Sourab98a@gmail.com  
 
Source of Monetary or Material Support  
Dr.D Y Patil Medical College and Hospital,Nerul ,Navi Mumbai 
 
Primary Sponsor  
Name  DrSourab Arora 
Address  Junior Resident Department of General Medicine Dr D Y Patil Medical College Navi Mumbai 400706 
Type of Sponsor  Other [Primary investigator] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Sourab Arora  D.Y Patil Medical college,Navi mumbai  OPD-1 (General Medicine OPD ) ,OPD -8 (GastrologyOPD ),Female Medicine Ward ,Male Medicine ward ,IIntensive Care Unit ,Dr D Y Patil Hospital Nerul,Navi Mumbai ,Maharashtra 400706 Thane MAHARASHTR
Thane
MAHARASHTRA 
9888302803

sourab98a@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee (IEC) for Biomedical and Health Research  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K920||Hematemesis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Nil  nil 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  1. Age: adults aged 18 and above.
2. Acute upper GI bleed: Patients presenting with signs and symptoms of acute upper
GI bleeding, which may include hematemesis (vomiting of blood), melena (dark,
tarry stools), or hematochezia (passage of fresh blood through the rectum).
3. Confirmed diagnosis: Patients with a confirmed diagnosis of acute upper GI bleeding
based on clinical evaluation and diagnostic tests.
4. Endoscopy: Patients who have undergone upper GI endoscopy as part of their
diagnostic evaluation.
 
 
ExclusionCriteria 
Details  Chronic GI bleeding: Patients with chronic or recurrent GI bleeding rather than acute bleeding.
2. Non-upper GI bleed: Patients with lower GI bleeding (e.g., colonic or rectal bleeding) rather than upper GI bleeding.
3. Known bleeding disorders: Patients with known bleeding disorders or coagulopathies that may affect the presentation or management of acute upper GI bleeding.
4. Previous upper GI surgery: Patients who have undergone previous upper GI surgery, as this may affect the endoscopic findings or clinical profile.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
1. To determine the frequency and distribution of different etiologies of acute UGIB.
2. To assess the presenting symptoms and signs of acute UGIB.
3. To determine the severity of acute UGIB using clinical and laboratory parameters.
4. To describe the endoscopic findings in patients with acute UGIB.
5. To assess the outcomes of patients with acute UGIB, including rebleeding, need for transfusion, need for endoscopic or surgical intervention, length of hospital stay, and mortality.
 
Baseline 1 year 
 
Secondary Outcome  
Outcome  TimePoints 
1-Two month follow-up recurrence   Baseline 1 year 
 
Target Sample Size   Total Sample Size="100"
Sample Size from India="100" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   24/02/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Open to Recruitment 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

This cross-sectional study aims to analyze the clinical and endoscopic profile of 100 patients presenting with acute upper gastrointestinal bleeding (UGIB) in a tertiary care hospital. By evaluating patient characteristics, endoscopic findings, and outcomes, the study will provide valuable insights into the diagnosis and management of UGIB. The results will help enhance clinical decision-making, improve patient outcomes, and potentially guide future research and practice guidelines in UGIB management.


 
Close